摘要
I. Problems in evaluating therapy for patients with hypertrophic cardiomyopathy A. Great variability in symptoms — day to day, week to week 1.
Often experience symptoms at rest that are difficult to quantitate (fatigue, lightheadedness, chest pain, dyspnea) 2.
Exercise end-point less reproducible than CAD patients B. Great variability in pathophysiologic spectrum: 1.
Obstructive vs nonobstructive 2.
NSR vs AF 3.
Decreased LV compliance vs. no or little change in compliance 4.
Increase pulmonary capillary wedge pressure vs. no or small increase in pressure. C.
This variability in symptoms and pathophysiologic spectrum results in the need to study a fairly large number of patients in order to avoid a Type II error (failure to detect a significant effect when, in fact, such exists), since sample size increases exponentially in relation to increases in the coefficient of variation of endpoint. KeywordsChest Pain Calcium Antagonist Exercise Capacity Hypertrophic Cardiomyopathy Beta Blocker These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves. This is a preview of subscription content, log in to check access.Preview
Unable to display preview. Download preview PDF.
Unable to display preview. Download preview PDF.
摘要译文
I.评估肥厚型心肌病患者治疗的问题A.症状的变异性很大 - 每天，每周一周1.经常出现难以定量的休息症状（疲劳，头晕，胸痛，呼吸困难）2。运动终点的可重复性低于CAD患者B.病理生理谱的变异性很大：1。阻塞性与非阻塞性2. NSR与房颤3.左心室顺应性降低与顺应性无关或变化不大4.增加肺毛细血管楔压与无或不压力小幅增加。 C.症状和病理生理学谱的这种可变性导致需要研究相当多的患者以避免II型错误（实际上存在这种情况时未能检测到显着效应），因为样本量呈指数增长与终点变异系数的增加有关。关键词肌肉疼痛钙拮抗剂运动能力肥厚性心肌病β阻滞剂这些关键词是通过机器而不是作者添加的。该过程是实验性的，并且可以在学习算法改进时更新关键字。这是订阅内容的预览，登录以检查access.PreviewUnable以显示预览。下载预览PDF。无法显示预览。下载预览PDF。
Stephen E. Epstein. Evaluation of Beta Blockers and Calcium Antagonists in the Treatment of Hypertrophic Cardiomyopathy. The Evaluation of Beta Blocker and Calcium Antagonist Drugs[M].DE: Springer, 1982: 377-379